Message #147 From:
Stock News Bot Date: October 30, 2006 03:00:00 AM
BIPH News Biophan to Present at Rodman and Renshaw 8th Annual Healthcare Conference
ROCHESTER, N.Y.--(BUSINESS WIRE)--Biophan Technologies, Inc. (OTCBB: BIPH;
FWB: BTN), a developer of next-generation biomedical technology, today
announced Michael Weiner, CEO, will present at the Rodman and Renshaw 8th
Annual Healthcare Conference on Tuesday, November 7, 2006, at 9:10 a.m.
ET. The three-day conference will be held November 6 to 8 at the New
York Plaza Hotel in New York City.
Biophan is dedicated to providing technologies that offer innovative and
competitive advantages to the medical device industry. The Company
licenses its technologies which improve the MRI safety and image
compatibility of medical devices to leading device manufacturers. In
addition, the Company is helping to commercialize the MYOTECH MYO-VAD™,
a new, MRI-compatible cardiac recovery system which has significant
potential to improve the treatment of many forms of heart disease.
Biophan is traded on the OTC market under the symbol BIPH, and is also
listed on the Frankfurt Stock Exchange under the symbol BTN. For more
information on Biophan, please visit our website at www.biophan.com.
Certain statements included in this press release may constitute
forward-looking statements within the meaning of applicable securities
laws. These statements reflect what Biophan anticipates, expects, or
believes may happen in the future. Biophan's actual results could differ
materially from the outcome or circumstance expressed or implied by such
forward-looking statements as a result of a variety of factors
including, but not limited to: Biophan's ability to develop its
technologies; the approval of Biophan's patent applications; the
successful implementation of Biophan's research and development
programs; the ability of Biophan to demonstrate the effectiveness of its
technology; the acceptance by the market of Biophan's technology and
products incorporating such technology; the ability of Biophan to
effectively negotiate and enter into contracts with medical device
manufacturers for the licensing of Biophan's technology; competition;
the ability of Biophan to raise capital to fund its operating and
research and development activities until it generates revenues
sufficient to do so; and the timing of projects and trends in future
operating performance, as well as other factors expressed from time to
time in Biophan's periodic filings with the Securities and Exchange
Commission (the "SEC"). As a result, this press release should be read
in conjunction with Biophan's periodic filings with the SEC, which are
incorporated herein by reference. The forward-looking statements
contained herein are made only as of the date of this press release, and
Biophan undertakes no obligation to publicly update such forward-looking
statements to reflect subsequent events or circumstances.
